Creating AI tools to predict vascular disease risk and progression
Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression
This study is trying to create smart computer tools that can predict the risk and progression of vascular diseases like abdominal aortic aneurysm and peripheral arterial disease by looking at medical images and patient history.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 11000 (estimated) |
| Ages | 40 Years to 90 Years |
| Sex | All |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Locations | 6 sites (Helsinki and 5 other locations) |
| Trial ID | NCT06206369 on ClinicalTrials.gov |
What this trial studies
The VASCULAID-RETRO study aims to develop artificial intelligence algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). By analyzing data from at least 5000 AAA and 6000 PAD patients, the study will utilize existing cohorts and retrospectively collected data. The AI tools will perform automatic anatomical segmentation and analyses on multimodal imaging, while prediction algorithms will be based on a combination of imaging, medical history, and -omics data. This innovative approach seeks to enhance the understanding of disease progression and risk assessment in vascular conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are males and females aged 40-90 with an AAA greater than 3cm or any stage of PAD.
Not a fit: Patients with ascending, thoracic, or thoracoabdominal aneurysms will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the ability to predict cardiovascular events and disease progression in patients with AAA and PAD.
How similar studies have performed: Other studies utilizing AI for predicting vascular disease risk have shown promise, indicating a potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males and females, 40-90 years old, with an AAA \>3cm. This includes patients with infrarenal, juxtarenal, suprarenal, iliac (defined as 1.5x its normal diameter) aneurysms, as well as mycotic aneurysms. Patients that have had interventions or ruptures will also be included * Males and females, 40-90 years old, all PAD patients (Fontaine stages 1,2,3, and 4). Exclusion Criteria: * Patients with an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.
Where this trial is running
Helsinki and 5 other locations
- Hospital District of Helsinki and Uusimaa (HUS) — Helsinki, Finland (Recruiting)
- Asklepios kliniken hamburg — Hamburg, Germany (Recruiting)
- Amsterdam UMC — Amsterdam, Netherlands (Recruiting)
- University Hospital Center of São João — Porto, Portugal (Recruiting)
- University Clinical Centre of Serbia — Belgrade, Serbia (Recruiting)
- Oxford University Hospitals — Oxford, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Kak Khee Yeung, MD, PhD
- Email: k.yeung@amsterdamumc.nl
- Phone: +31 6 14278725
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.